Payer-Negotiated Prices in the Diagnosis and Management of Thyroid Cancer in 2021.
Where this comes from
- Record sourced from PubMed, PMID 34086052.
- Also identified by DOI 10.1001/jama.2021.8535 and PMC identifier PMC4240626.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study examines price availability and variation for thyroid cancer care at National Cancer Institute (NCI)–Designated Cancer Centers following a 2021 CMS policy reform requiring hospitals to disclose commercial payer-specific negotiated prices for all items and services.